Posted by Michael Wonder on 15 Nov 2021
Rhythm Pharmaceuticals announces FDA acceptance for filing and priority review of supplemental new drug application for Imcivree (setmelanotide) for patients with Bardet-Biedl syndrome and Alström syndrome
15 November 2021 - FDA sets PDUFA goal date of 16 March 2022.
Rhythm Pharmaceuticals today announced that the U.S. FDA has accepted for filing the company’s supplemental new drug application for Imcivree (setmelanotide) for patients with Bardet-Biedl syndrome or Alström syndrome.
